Kinevac Related Published Studies
Well-designed clinical trials possibly related to Kinevac (Sincalide)
Effect of viscosity on appetite and gastro-intestinal hormones. [2009.04.20]
A high-fat diet raises fasting plasma CCK but does not affect upper gut motility, PYY, and ghrelin, or energy intake during CCK-8 infusion in lean men. [2008.01]
Effects of long term hydrophilic bile acid therapy on in vitro contraction of gallbladder muscle strips in patients with cholesterol gallstones. [2007.08.28]
Variation in exocrine pancreatic secretion in rats due to different commercial diets. [2006.06]
Use of cholecystokinin-octapeptide for the prevention of parenteral nutrition-associated cholestasis. [2005.05]
Failure of cholecystokinin-octapeptide to prevent TPN-associated gallstone disease. [2005.01]
Other research related to Kinevac (Sincalide)
Sincalide-stimulated cholescintigraphy: a multicenter investigation to determine optimal infusion methodology and gallbladder ejection fraction normal values. [2010.02]
Other possibly related research studies
The ghrelin pentapeptide inhibits the secretion of pancreatic juice in rats. [2006.12]
Subclinical exocrine pancreatic dysfunction resulting from decreased cholecystokinin secretion in the presence of intestinal villous atrophy. [2006.09]
The ontogeny of postingestive inhibitory stimuli: examining the role of CCK. [2006.07]
Ethanol sensitizes NF-kappaB activation in pancreatic acinar cells through effects on protein kinase C-epsilon. [2006.09]
Inhibitory effect of Patrinia scabiosaefolia on acute pancreatitis. [2006.02.21]
Involvement of cholecystokinin in peripheral nociceptive sensitization during diabetes in rats as revealed by the formalin response. [2006.05]
Beneficial effect of resveratrol on cholecystokinin-induced experimental pancreatitis. [2006.02.17]
Gallbladder histopathology during murine gallstone formation: relation to motility and concentrating function. [2006.01]
The proteasome inhibitor MG132 protects against acute pancreatitis. [2005.11.01]
Changes in the satiating effect of cholecystokinin over repeated trials. [2005.07.21]
Inhibitory effects on intake of cholecystokinin-8 and cholecystokinin-33 in rats with hepatic proper or common hepatic branch vagal innervation. [2005.08]
CCK inhibits the orexigenic effect of peripheral ghrelin. [2005.03]
Corn oil emulsion: a simple cholecystagogue for diagnosis of chronic acalculous cholecystitis. [2005.01]
Periaqueductal gray cholecystokinin infusions block morphine-induced disruption of maternal behavior. [2007.03]
Microinjection of exogenous somatostatin in the dorsal vagal complex inhibits pancreatic secretion via somatostatin receptor-2 in rats. [2007.03]
Intravenous CCK-8, but not GLP-1, suppresses ghrelin and stimulates PYY release in healthy men. [2007.03]
Effects of cholecystokinin-8s in the nucleus tractus solitarius of vagally deafferented rats. [2007.03]
Determination of the biliary excretion of piperacillin in humans using a novel method. [2006.09]
Nanostructures by self-assembling peptide amphiphile as potential selective drug carriers. [2007]
Gastric vagal efferent inhibition evoked by intravenous CRF is unrelated to simultaneously recorded vagal afferent activity in urethane-anesthetized rats. [2007.04]
Vagally mediated, nonparacrine effects of cholecystokinin-8s on rat pancreatic exocrine secretion. [2007.08]
Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist. [2007.05]
Zerumbone exerts a beneficial effect on inflammatory parameters of cholecystokinin octapeptide-induced experimental pancreatitis but fails to improve histology. [2007.10]
Electroacupuncture protects against CCK-induced acute pancreatitis in rats. [2007]
Cholecystokinin CCK2 receptors mediate the peptide's inhibitory actions on the contractile activity of human distal colon via the nitric oxide pathway. [2007.08]
Role of the amygdaloid cholecystokinin (CCK)/gastrin-2 receptors and terminal networks in the modulation of anxiety in the rat. Effects of CCK-4 and CCK-8S on anxiety-like behaviour and [3H]GABA release. [2007.12]
[Effect of acupotomy lysis on SP and CCK-8 contents in hypothalamus and spinal cord in rats with transverse process syndrome of the third lumbar vertebra] [2008.02]
Tachykinin neurokinin 3 receptor signaling in cholecystokinin-elicited release of oxytocin and vasopressin. [2008.05]
Effects of bee venom on cholecystokinin octapeptide-induced acute pancreatitis in rats. [2008.03]
Tonic and phasic pyloric activity in response to CCK-octapeptide. [2008.04]
A cholecystokinin-1 receptor agonist (CCK-8) mediates increased permeability of brain barriers to leptin. [2008.07]
[Pirh2 shRNA mediated by psiRNA-hH1 vector plasmid effectively inhibits the proliferation of lung carcinoma cells: in vitro and in vivo experiments] [2007.05.08]
Cholecystokinin-58 is more potent in inhibiting food intake than cholecystokinin-8 in rats. [2008.04]
[Regulation of axon guidance cue netrin-1 on angiogenesis] [2007.02.13]
Interventions used with cholescintigraphy for the diagnosis of hepatobiliary disease. [2009.05]
A high-fat diet attenuates the central response to within-meal satiation signals and modifies the receptor expression of vagal afferents in mice. [2009.06]
NMDA NR2 receptors participate in CCK-induced reduction of food intake and hindbrain neuronal activation. [2009.04.17]
Cholecystokinin-8 sulfate modulates the anticonvulsant efficacy of vigabatrin in an experimental model of partial complex epilepsy in the rat. [2009.04]
Phenotype of neurons in the nucleus of the solitary tract that express CCK-induced activation of the ERK signaling pathway. [2009.04]
The roles of nerve growth factor and cholecystokinin in the enhancement of morphine analgesia in a rodent model of central nervous system inflammation. [2009.03]
Sphincter of Oddi dysfunction in hypercholesterolemic rabbits. [2008.03]
[Cholecystokinin octapeptide augments expression of anti-inflammatory cytokines in mice challenged by lipopolysaccharide] [2007.10]
New method of manometric measurement of gastroduodenal motility in conscious mice: effects of ghrelin and Y2 depletion. [2009.11]
Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype. [2010.07]
Quinacrine enhances cisplatin-induced cytotoxicity in four cancer cell lines. [2010]
Extended application of 99mTc-mebrofenin cholescintigraphy with cholecystokinin in the evaluation of abdominal pain of hepatobiliary and gastrointestinal origin. [2010.05]
Comparison between two kinds of cigarette smoke condensates (CSCs) of the cytogenotoxicity and protein expression in a human B-cell lymphoblastoid cell line using CCK-8 assay, comet assay and protein microarray. [2010.03.29]
Dose-related effects of cholecystokinin octapeptide administered during various phases of the migrating motor complex on small-intestinal motility in sheep. [2009.12]
CCK-8S activates c-Fos in a dose-dependent manner in nesfatin-1 immunoreactive neurons in the paraventricular nucleus of the hypothalamus and in the nucleus of the solitary tract of the brainstem. [2009.10.09]
Acetyl-L-carnitine ameliorates spatial memory deficits induced by inhibition of phosphoinositol-3 kinase and protein kinase C. [2011.09]
Emodin potentiates the antitumor effects of gemcitabine in pancreatic cancer cells via inhibition of nuclear factor-kappaB. [2011.03]
Cholecystokinin-cholescintigraphy in adults: consensus recommendations of an interdisciplinary panel. [2011.05]
Additive effects of cannabinoid CB1 receptors blockade and cholecystokinin on feeding inhibition. [2011.04]
Rapakinin, Arg-Ile-Tyr, derived from rapeseed napin, shows anti-opioid activity via the prostaglandin IP receptor followed by the cholecystokinin CCK(2) receptor in mice. [2011.02]
Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 beta production in a cancer-induced pain model in mice. [2010.10.28]
Anti-inflammatory action of cholecystokinin and melatonin in the rat parotid gland. [2010.10]
The anorexigenic effect of cholecystokinin octapeptide in a goldfish model is mediated by the vagal afferent and subsequently through the melanocortin- and corticotropin-releasing hormone-signaling pathways. [2010.11]
Repeated administration of methamphetamine blocked cholecystokinin-octapeptide injection-induced c-fos mRNA expression without change in capsaicin-induced junD mRNA expression in rat cerebellum. [2010.09]
Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells. [2011]
|